Tag: Johnson & Johnson

‘I Have a Vision for Helping Advance Healthcare’: Meet 6 Leaders Working on Inspiring Innovations in 2020

Originally published on jnj.com. From robotics solutions for orthopedic surgery to the potential to bring new hope to patients living with multiple myeloma through CAR-T, these are just some of the cutting-edge projects that these visionaries think could potentially help propel healthcare forward around the globe. As 2019 came to…

Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak

Originally published on jnj.com. Up to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC) Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the…

J&J, Hershey, EY and Others Champion Career Advancement for People of Color in Supply Chain Roles

Ensuring diversity and inclusivity in the workplace doesn’t just happen, individuals and organizations must take action to do things differently. Johnson& Johnson, The Hershey Company and EY created a coalition aimed at creating opportunities to advance people of color in supply chain jobs that plan, source, make and deliver products….

New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function

Originally Published by Johnson & Johnson Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart…

Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review

Originally Published by Johnson & Johnson Johnson & Johnson (NYSE: JNJ), the world’s largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic Diversity & Inclusion (D&I) philosophy has been a key driver of innovation and impactful business outcomes since…

Johnson & Johnson: XARELTO Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

Originally posted on JNJ.com The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) – or blood clots – and similar…